Gilead, Cognizant

Cognizant Expands Partnership with Gilead
Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology applications. By deploying these solutions across the value chain, Cognizant aims to help Gilead achieve significant benefits through a newly optimized financial framework.
Cognizant expands AI services for Gilead Sciences
Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ: NASDAQ:GILD), aiming to enhance Gilead's customer service, employee engagement,
Cognizant Expands Partnership With Gilead Sciences To Enhance Efficiency And AI Integration
Thursday announced that it has expanded its long-standing collaboration with Gilead Sciences (GILD) to enhance cost
Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as it advances innovations to prevent and treat life-threatening diseases.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Cognizant, Gilead expand relationship
Cognizant (CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (GILD) that aims to
Breaking Down Gilead Sciences: 22 Analysts Share Their Views
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...
Gilead Worker Accused of Sex Harassment Advances Defamation Suit
Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...
Gilead Sciences' SWOT analysis: stock outlook shaped by HIV and oncology progress
Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. closed 3.35% below its 52-week high of $98.90, which the company achieved on November 11th.
Business Wire2d
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...
Zacks.com on MSN2d
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.
Gilead Sciences Inc. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.